Author:
Fortmann Seth D.,Rao Sunil V.,Tanguay Jean-Francois,Lordkipanidze Marie,Hanley Daniel F.,Can Mehmet,Kim Moo Hyun,Marciniak Thomas A.,Serebruany Victor L.
Abstract
SummaryVorapaxar, a novel antiplatelet thrombin PAR-1 inhibitor, has been evaluated in the successful TRA2P trial and the failed TRACER trial. The drug is currently approved for post myocardial infarction and peripheral artery disease indications with concomitant use of clopidogrel and/or aspirin. The FDA ruled that the vorapaxar safety profile is acceptable. However, both trials revealed excess diplopia (double vision) usually reversible after vorapaxar. The diplopia risk appears to be small (about 1 extra case per 1,000 treated subjects), but real. Overall, there were 10 placebo and 34 vorapaxar diplopia cases (p=0.018) consistent for TRACER (2 vs 13 cases; p=0.010) and for TRA2P (8 vs 21 cases; p=0.018). Hence, we review the FDA-confirmed evidence and discuss potential causes and implications of such a surprising adverse association, which may be related to off-target PAR receptor mismodulation in the eye.
Reference43 articles.
1. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes
2. Tricoci P, Huang Z, Held C, et al.; the TRACER Investigators. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. N Engl J Med 2012; 366: 20-33
3. Vorapaxar in the Secondary Prevention of Atherothrombotic Events
4. NDA 294-886. Medical reviews on Vorapaxar. June 18th, 2014 Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s000MedR.pdf. Accessed May 15, 2015
5. NDA 294-886. Cross-discipline Team Leader review on Vorapaxar. April 18th, 2014 Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s000SumR.pdf. Accessed May 15, 2015
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献